Ischemic Heart Failure Clinical Trial
Official title:
A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure
This is a randomized, double-blind, placebo controlled Phase II study is designed to assess the safety and efficacy of using JVS-100 to treat heart failure.
90 subjects with ischemic cardiomyopathy will be randomized to receive a single dose of 15 or 30 mg of JVS-100 or matching placebo. Subjects will be randomized 1:1:1 to receive either placebo, 15 mg or 30 mg of JVS-100. Subjects will be monitored overnight for 18-24 hours post dose and have scheduled visits at 3 days post-injection for safety evaluations. All subjects will be scheduled for follow-up visits at approximately 30 days (1 month), 120 days (4 months), and 360 days (12 months) to assess safety and cardiac function. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02240940 -
PARACHUTE China Approval Trial
|
N/A | |
Completed |
NCT00846001 -
Resynchronization Surgery Combined Unified Efficacy
|
Phase 3 | |
Recruiting |
NCT05566600 -
Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure
|
Early Phase 1 | |
Active, not recruiting |
NCT01961726 -
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Terminated |
NCT00102128 -
Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.
|
Phase 2 | |
Not yet recruiting |
NCT03491969 -
Clinical Study of Lipoic Acid on Ischemic Heart Failure
|
Phase 4 | |
Recruiting |
NCT01555320 -
Clinical Assessment of Complementary Treatment With Qishen Yiqi Dripping Pills on Ischemic Heart Failure
|
N/A | |
Recruiting |
NCT02875639 -
A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)
|
Phase 2 | |
Completed |
NCT02700880 -
LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry
|
||
Active, not recruiting |
NCT02115568 -
Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203
|
N/A | |
Recruiting |
NCT03206593 -
Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure
|
N/A | |
Enrolling by invitation |
NCT01709279 -
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
|
N/A | |
Not yet recruiting |
NCT06258447 -
CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction
|
N/A |